



Silence Therapeutics to Participate in Three September Investor Conferences

2026-09-02

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and invited investors to participate by webcast.

- Cantor Global Healthcare Conference 2026
Fireside chat on Wednesday, September 9, 2026 at 10:55 a.m. ET
- H.C. Wainwright 28th Annual Global Investment Conference
Fireside chat on Tuesday, September 15, 2026 at 3:00 p.m. ET
- Morgan Stanley 24th Annual Global Healthcare Conference
Fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. ET

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com/events. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit <https://www.silence-therapeutics.com/>.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260902345520/en/>

Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc